35356894|t|Improving the Safety of Mesenchymal Stem Cell-Based Ex Vivo Therapy Using Herpes Simplex Virus Thymidine Kinase.
35356894|a|Human mesenchymal stem cells (MSCs) are multipotent stem cells that have been intensively studied as therapeutic tools for a variety of disorders. To enhance the efficacy of MSCs, therapeutic genes are introduced using retroviral and lentiviral vectors. However, serious adverse events (SAEs) such as tumorigenesis can be induced by insertional mutagenesis. We generated lentiviral vectors encoding the wild-type herpes simplex virus thymidine kinase (HSV-TK) gene and a gene containing a point mutation that results in an alanine to histidine substitution at residue 168 (TK(A168H)) and transduced expression in MSCs (MSC-TK and MSC-TK(A168H)). Transduction of lentiviral vectors encoding the TK(A168H) mutant did not alter the proliferation capacity, mesodermal differentiation potential, or surface antigenicity of MSCs. The MSC-TK(A168H) cells were genetically stable, as shown by karyotyping. MSC-TK(A168H) responded to ganciclovir (GCV) with an half maximal inhibitory concentration (IC50) value 10-fold less than that of MSC-TK. Because MSC-TK(A168H) cells were found to be non-tumorigenic, a U87-TK(A168H) subcutaneous tumor was used as a SAE-like condition and we evaluated the effect of valganciclovir (vGCV), an oral prodrug for GCV. U87-TK(A168H) tumors were more efficiently ablated by 200 mg/kg vGCV than U87-TK tumors. These results indicate that MSC-TK(A168H) cells appear to be pre-clinically safe for therapeutic use. We propose that genetic modification with HSV-TK(A168H) makes allogeneic MSC-based ex vivo therapy safer by eliminating transplanted cells during SAEs such as uncontrolled cell proliferation.
35356894	74	111	Herpes Simplex Virus Thymidine Kinase	Species	
35356894	113	118	Human	Species	9606
35356894	414	427	tumorigenesis	Disease	MESH:D063646
35356894	526	563	herpes simplex virus thymidine kinase	Species	
35356894	565	571	HSV-TK	Species	
35356894	636	684	alanine to histidine substitution at residue 168	ProteinMutation	tmVar:p|SUB|A|168|H;HGVS:p.A168H;VariantGroup:0
35356894	689	694	A168H	ProteinMutation	tmVar:p|SUB|A|168|H;HGVS:p.A168H;VariantGroup:0
35356894	750	755	A168H	ProteinMutation	tmVar:p|SUB|A|168|H;HGVS:p.A168H;VariantGroup:0
35356894	810	815	A168H	ProteinMutation	tmVar:p|SUB|A|168|H;HGVS:p.A168H;VariantGroup:0
35356894	941	945	MSC-	CellLine	CVCL:U446
35356894	948	953	A168H	ProteinMutation	tmVar:p|SUB|A|168|H;HGVS:p.A168H;VariantGroup:0
35356894	1018	1023	A168H	ProteinMutation	tmVar:p|SUB|A|168|H;HGVS:p.A168H;VariantGroup:0
35356894	1038	1049	ganciclovir	Chemical	MESH:D015774
35356894	1051	1054	GCV	Chemical	MESH:D015774
35356894	1164	1169	A168H	ProteinMutation	tmVar:p|SUB|A|168|H;HGVS:p.A168H;VariantGroup:0
35356894	1213	1216	U87	CellLine	CVCL:0022
35356894	1220	1225	A168H	ProteinMutation	tmVar:p|SUB|A|168|H;HGVS:p.A168H;VariantGroup:0
35356894	1240	1245	tumor	Disease	MESH:D009369
35356894	1310	1324	valganciclovir	Chemical	MESH:D000077562
35356894	1326	1330	vGCV	Chemical	MESH:D000077562
35356894	1353	1356	GCV	Chemical	MESH:D015774
35356894	1358	1361	U87	CellLine	CVCL:0022
35356894	1365	1370	A168H	ProteinMutation	tmVar:p|SUB|A|168|H;HGVS:p.A168H;VariantGroup:0
35356894	1372	1378	tumors	Disease	MESH:D009369
35356894	1422	1426	vGCV	Chemical	MESH:D000077562
35356894	1432	1435	U87	CellLine	CVCL:0022
35356894	1439	1445	tumors	Disease	MESH:D009369
35356894	1482	1487	A168H	ProteinMutation	tmVar:p|SUB|A|168|H;HGVS:p.A168H;VariantGroup:0
35356894	1591	1597	HSV-TK	Species	
35356894	1598	1603	A168H	ProteinMutation	tmVar:p|SUB|A|168|H;HGVS:p.A168H;VariantGroup:0
35356894	Association	MESH:D015774	HGVS:p.A168H
35356894	Negative_Correlation	MESH:D000077562	MESH:D009369
35356894	Cotreatment	MESH:D000077562	MESH:D015774

